78767-55-2

Basic information

• Product Name: BENZOIC ACID, 4-FORMYL-, PHENYLMETHYL ESTER
• Synonyms: BENZOIC ACID, 4-FORMYL-, PHENYLMETHYL ESTER;benzyl 4-formylbenzoate
• CAS NO: 78767-55-2
• Molecular Formula: C₁₅H₁₂O₃
• Molecular Weight: 240.25398
• Mol File: 78767-55-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: BENZOIC ACID, 4-FORMYL-, PHENYLMETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: BENZOIC ACID, 4-FORMYL-, PHENYLMETHYL ESTER(78767-55-2)
• EPA Substance Registry System: BENZOIC ACID, 4-FORMYL-, PHENYLMETHYL ESTER(78767-55-2)

Safety Data

• Hazardous Substances Data: 78767-55-2(Hazardous Substances Data)

Upstream product

• 619-66-9 4-Carboxybenzaldehyde 
• 100-51-6 benzyl alcohol 
• 100-39-0 benzyl bromide 
• 99-96-7 4-hydroxy-benzoic acid 
• 31139-36-3 dibenzyl dicarbonate 
• 86988-50-3 4-(2,2,2-trifluoroacetyl)benzaldehyde 
• 104367-76-2 4-Carbobenzoxyphenylaldoxime 

Downstream Products

• 159675-81-7 tert-butyl 4-(benzyloxycarbonyl)-α-methylcinnamate 
• 18520-63-3 monobenzyl terephthalate 
• 1003314-81-5 4-[(dimethoxy-phosphoryl)-hydroxy-methyl]-benzoic acid benzyl ester 
• 1401717-19-8 C₁₅H₂₁NO₄ 
• 1401717-20-1 C₂₄H₂₉N₃O₇ 
• 1401717-21-2 C₁₆H₂₃N₃O₅ 
• 1401717-22-3 C₃₄H₄₆N₆O₁₀ 
• 1401717-23-4 C₂₈H₃₆N₆O₈ 
• 1401717-24-5 C₂₉H₃₈N₆O₈ 
• 1401717-35-8 C₂₀H₂₂N₆O₆*ClH 
• 1266617-61-1 2,5-dioxopyrrolidin-1-yl 4-(4,4-difluoro-1,3,5,7-tetramethyl-3a,4a-diaza-4-bora-s-indacen-8-yl)benzoate 
• 1609466-54-7 (R,Z)-2-(5-(4-((benzyloxy)carbonyl)benzylidene)-4-oxo-2-thioxothiazolidin-3-yl)-3-phenylpropanoic acid 
• 1181812-01-0 diethyl α-hydroxy-4-carbobenzyloxybenzylphosphonate 

Relevant articles and documents

Spatially Resolved Covalent Functionalization Patterns on Graphene

Spatially resolved functionalization of 2D materials is highly demanded but very challenging to achieve. The chemical patterning is typically tackled by preventing contact between the reagent and material, which brings various accompanying challenges. Photochemical transformation on the other hand inherently provides remote high spatiotemporal resolution using the cleanest reagent—a photon. Herein, we combine two competing reactions on a graphene substrate to create functionalization patterns on a micrometer scale via the Mitsunobu reaction. The mild reaction conditions allow introduction of covalently dynamic linkages, which can serve as reversible labels for surface- or graphene-enhanced Raman spectroscopy characterization of the patterns prepared. The proposed methodology thus provides a pathway for local introduction of arbitrary functional groups on graphene.

Creation of Fluorescent RXR Antagonists Based on CBTF-EE and Application to a Fluorescence Polarization Binding Assay

Retinoid X receptor (RXR) ligands often bind in modes in which the carboxy group forms a hydrogen bond inside the ligand-binding pocket (LBP). However, our previously reported RXR antagonist, CBTF-EE (4a), binds with its carboxy group directed outside the LBP and its alkoxy side chain located inside the LBP. Here, we examined the binding modes of 4b and 4c bearing a nitrobenzoxadiazole (NBD) or boron-dipyrromethene (BODIPY) fluorophore, respectively, at the end of the alkoxy chain of 4a. Both compounds function as RXR antagonists. 4c, but not 4b, was available for a fluorescence polarization binding assay, indicating that rotation of BODIPY, but not NBD, is restricted in the bound state. The fluorescence findings, supported by docking simulations, suggest the fluorophores are located outside the LBP, so that the binding mode of 4b and 4c is different from that of 4a. The assay results were highly correlated with those of a [3H]9-cis-retinoic acid assay.

Combined Cardioprotective and Adipocyte Browning Effects Promoted by the Eutomer of Dual sEH/PPARγModulator

The metabolic syndrome (MetS) is a constellation of cardiovascular and metabolic symptoms involving insulin resistance, steatohepatitis, obesity, hypertension, and heart disease, and patients suffering from MetS often require polypharmaceutical treatment.

Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia

Epigenetic targeting has emerged as an efficacious therapy for hematological cancers. The rare and incurable T-cell prolymphocytic leukemia (T-PLL) is known for its aggressive clinical course. Current epigenetic agents such as histone deacetylase (HDAC) inhibitors are increasingly used for targeted therapy. Through a structure-activity relationship (SAR) study, we developed an HDAC6 inhibitor KT-531, which exhibited higher potency in T-PLL compared to other hematological cancers. KT-531 displayed strong HDAC6 inhibitory potency and selectivity, on-target biological activity, and a safe therapeutic window in nontransformed cell lines. In primary T-PLL patient cells, whereHDAC6was found to be overexpressed, KT-531 exhibited strong biological responses, and safety in healthy donor samples. Notably, combination studies in T-PLL patient samples demonstrated KT-531 synergizes with approved cancer drugs, bendamustine, idasanutlin, and venetoclax. Our work suggests HDAC inhibition in T-PLL could afford sufficient therapeutic windows to achieve durable remission either as stand-alone or in combination with targeted drugs.

PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia

Dysregulated Histone Deacetylase (HDAC) activity across multiple human pathologies have highlighted this family of epigenetic enzymes as critical druggable targets, amenable to small molecule intervention. While efficacious, current approaches using non-selective HDAC inhibitors (HDACi) have been shown to cause a range of undesirable clinical toxicities. To circumvent this, recent efforts have focused on the design of highly selective HDACi as a novel therapeutic strategy. Beyond roles in regulating transcription, the unique HDAC6 (with two catalytic domains) regulates the deacetylation of α-tubulin; promoting growth factor-controlled cell motility, cell division, and metastatic hallmarks. Recent studies have linked aberrant HDAC6 function in various hematological cancers including acute myeloid leukaemia and multiple myeloma. Herein, we report the discovery, in vitro characterization, and biological evaluation of PTG-0861 (JG-265), a novel HDAC6-selective inhibitor with strong isozyme-selectivity (～36× ) and low nanomolar potency (IC50 = 5.92 nM) against HDAC6. This selectivity profile was rationalized via in silico docking studies and also observed in cellulo through cellular target engagement. Moreover, PTG-0861 achieved relevant potency against several blood cancer cell lines (e.g. MV4-11, MM1S), whilst showing limited cytotoxicity against non-malignant cells (e.g. NHF, HUVEC) and CD-1 mice. In examining compound stability and cellular permeability, PTG-0861 revealed a promising in vitro pharmacokinetic (PK) profile. Altogether, in this study we identified a novel and potent HDAC6-selective inhibitor (～4× more selective than current clinical standards – citarinostat, ricolinostat), which achieves cellular target engagement, efficacy in hematological cancer cells with a promising safety profile and in vitro PK.

Design, synthesis and biological evaluation of benzimidazole derivatives as novel human Pin1 inhibitors

In this work, a series of novel benzimidazole derivatives were designed and synthesized as Pin1 inhibitors. Protease-coupled assay was used to investigate the Pin1 inhibitory potency of all synthesized compounds. Thirteen of them showed preferable Pin1 inhibitory effects with IC50 values lower than 5 μM, and 12a, 15b, 15d and 16c exhibited the most promising Pin1 inhibitory activity at low micromolar level (0.33–1.00 μM) than the positive control compound Juglone. Flow cytometry results showed that treating PC-3 cells with 16c caused slight cycle arrest in a concentration-dependent manner. The structure-activity relationships of R1, R2, R3 and linker of the benzimidazole derivatives were analyzed in detail, which would help further exploration of new Pin1 inhibitors.

1,2-dis-substituted benzimidazole derivative and application thereof

The invention belongs to the technical field of medicines, and particularly relates to a 1,2-dis-substituted benzimidazole derivative and pharmaceutically acceptable salt thereof, a preparation method of the derivative, a medicine composition with the derivative serving as an active component, and application of the derivative in preparation of a Pin1 inhibitor and preparation of a medicine for treating and/or preventing various cancers. The 1,2-dis-substituted benzimidazole derivative and the pharmaceutically acceptable salt thereof are as shown in the general formula I, and definitions of all substituents are described in claims and the specification. (Refer to Specification).

Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy

Inhibition of cyclin dependent kinase 2 (CDK2) in complex with cyclin A in G1/S phase of the cell cycle has been shown to promote selective apoptosis of cancer cells through the E2F1 pathway. An alternative approach to catalytic inhibition is to target the substrate recruitment site also known as the cyclin binding groove (CBG) to generate selective non-ATP competitive inhibitors. The REPLACE strategy has been applied to identify fragment alternatives and substituted benzoic acid derivatives were evaluated as a promising scaffold to present appropriate functionality to mimic key peptide determinants. Fragment Ligated Inhibitory Peptides (FLIPs) are described which potently inhibit both CDK2/cyclin A and CDK4/cyclin D1 and have preliminary anti-tumor activity. A structural rationale for binding was obtained through molecular modeling further demonstrating their potential for further development as next generation non ATP competitive CDK inhibitors.

Malachite green artificial antigen and antibody and its preparation method and application

The invention provides preparation of malachite green artificial antigen and antibody, and relates to preparation of artificial hapten, artificial antigen and antibody of a triphenylmethane chemical substance malachite green. By adopting the preparation method, the problems of complex process, high cost and low analysis speed of the traditional physical and chemical analysis method are overcome. A simple, convenient, quick, sensitive and accurate enzyme immunoassay is provided. The method comprises the following steps: taking 4-[bi(4-dimethylamino)phenyl]methyl benzoic acid and 5-{4-[bi-(4-dimethylamino)phenyl]methyl} phenyl valeric acid as haptens to be respectively connected with carrier proteins such as hemocyanin, ovalbumin and the like to synthetize artificial antigen; carrying out animal immunization, taking blood, separating out antiserum, and purifying, so as to prepare the antibody. The antibody is stable, and has good specificity and sensitivity, and a good application prospect, and can be applied to fast immunodetection of the malachite green.

ALLOSTERIC MODULATORS OF FACTOR XIa AS ANTICOAGULANT AGENTS

Compounds which allosterically modulate and/or inhibit factor XIa activity are provided, as are methods of their use. These compounds include i) sulfated gallolyl glucosides, ii) sulfated quinazolinones, and iii) sulfated inositol analogs. The compounds used as anticoagulant agents.